Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
LOS ANGELES, June 12, 2017 -- Lundin Law PC, a shareholder rights firm, announces the filing of a class action lawsuit against Roche Holding AG (“Roche Holding” or the “Company”) (Other OTC:RHHBY) for possible violations of federal securities laws between March 2, 2017 and June 5, 2017, inclusive (the “Class Period”). Investors who purchased or otherwise acquired shares during the Class Period should contact the firm prior to the August 7, 2017 lead plaintiff motion deadline.
To participate in this class action lawsuit, click here.
You can also call Brian Lundin, Esq., of Lundin Law PC, at 888-713-1033, or e-mail him at [email protected].
No class has been certified in the above action yet. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.
According to the Complaint, throughout the Class Period, Roche Holding issued materially false and misleading statements and/or failed to disclose that the combination of the Company’s breast cancer drug, Perjeta, and its older treatment, Herceptin, is only marginally more effective than Herceptin alone in preventing breast cancer; and that as a result, Roche Holding’s statements about its business, operations and prospects were materially false and misleading and/or lacked a reasonable bases at all relevant times. When this information was released to the public, shares of Roche Holding fell in value, causing investors harm according to the Complaint.
Lundin Law PC was established by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Contact: Lundin Law PC Brian Lundin, Esq. Telephone: 888-713-1033 Facsimile: 888-713-1125 [email protected] http://lundinlawpc.com/
